PBAC's latest decision on Fentanyl citrate: Recommended with restriction (2017). Considered for Initial treatment for dose titration of cancer patients with breakthrough pain (BTP) attributable to cancer, in patients already receiving maintenance opioid therapy for chronic pain.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
7
first 2006
Submissions
7
2006 → 2017
Eligible population
Adult cancer patients with breakthrough pain who are already receiving maintenance opioid therapy for chronic pain, during the initial dose titration phase of treatment.
Therapy area
Pain
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Economic model
BIA only
ICER note
Minor submission; no economic evaluation or ICER calculated.
ICER (historical)
$45k/QALY–$75k/QALY in an earlier submission (2007) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Mar 2006: Not recommended
Nov 2007: Recommended with restriction · Authority Required — ICER $75k/QALY
Mar 2013: Not recommended · Not applicable
Jul 2015: Recommended with restriction · Authority Required
Jul 2015: Recommended with restriction · Authority Required
Nov 2015: Recommended with restriction · Authority Required
Jul 2017: Recommended with restriction · Restricted